Influenza immunization for adults 18 years and older Report uri icon
  • This report summarizes estimates of health impact and cost-effectiveness of influenza immunization for adults 18 years and older that were created to assess the relative value of most of the clinical preventive services recommended by the United States Preventive Services Task Force (USPSTF) and the Advisory Committee on Immunization Practices (ACIP) for the general population. This ranking of clinical prevention priorities is guided by the National Commission on Prevention Priorities (NCPP).

    This report describes the methods, evidence, clinically preventable burden and Cost-effectiveness of offering influenza vaccine to a birth cohort of 4 million individuals. It builds on a prior report of the value of influenza immunization for ages 50 and older. In 2010, the Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for annual seasonal influenza vaccination to include healthy adults aged 18 to 49. Our main results are for all ages combined, but results are also stratified by age groups reflecting changes in the ACIP recommendation over time (18-49 years, 50 to 64 years, 65 years and older).

    The estimates in this report may not reflect current USPSTF recommendations. Readers are advised to check for updated recommendations at and

  • publication date
  • 2017
  • Research
  • Economics
  • Influenza
  • Influenza Vaccines
  • Prevention
  • Additional Document Info
  • 17-02